These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 25761935)

  • 1. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.
    Gañán-Gómez I; Wei Y; Starczynowski DT; Colla S; Yang H; Cabrero-Calvo M; Bohannan ZS; Verma A; Steidl U; Garcia-Manero G
    Leukemia; 2015 Jul; 29(7):1458-69. PubMed ID: 25761935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deconstructing innate immune signaling in myelodysplastic syndromes.
    Varney ME; Melgar K; Niederkorn M; Smith M; Barreyro L; Starczynowski DT
    Exp Hematol; 2015 Aug; 43(8):587-598. PubMed ID: 26143580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS.
    Trowbridge JJ; Starczynowski DT
    J Exp Med; 2021 Jul; 218(7):. PubMed ID: 34129017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inflammatory microenvironment in MDS.
    Yang L; Qian Y; Eksioglu E; Epling-Burnette PK; Wei S
    Cell Mol Life Sci; 2015 May; 72(10):1959-66. PubMed ID: 25662443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate immune signaling in the myelodysplastic syndromes.
    Starczynowski DT; Karsan A
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):343-59. PubMed ID: 20359630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes.
    Mattiucci D; Maurizi G; Leoni P; Poloni A
    Cell Transplant; 2018 May; 27(5):754-764. PubMed ID: 29682980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic immune response dysregulation in MDS pathogenesis.
    Barreyro L; Chlon TM; Starczynowski DT
    Blood; 2018 Oct; 132(15):1553-1560. PubMed ID: 30104218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow niche in the myelodysplastic syndromes.
    Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
    Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.
    Ivy KS; Brent Ferrell P
    Curr Hematol Malig Rep; 2018 Aug; 13(4):244-255. PubMed ID: 29934935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
    Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
    J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
    Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
    Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice.
    Wei Y; Zheng H; Bao N; Jiang S; Bueso-Ramos CE; Khoury J; Class C; Lu Y; Lin K; Yang H; Ganan-Gomez I; Starczynowski DT; Do KA; Colla S; Garcia-Manero G
    Blood Adv; 2018 Oct; 2(19):2491-2504. PubMed ID: 30275007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.
    Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA
    Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes.
    Cull AH; Rauh MJ
    J Leukoc Biol; 2017 Aug; 102(2):209-219. PubMed ID: 28596252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of interferon signaling genes in the bone marrow microenvironment of myelodysplastic syndromes.
    Kim M; Hwang S; Park K; Kim SY; Lee YK; Lee DS
    PLoS One; 2015; 10(3):e0120602. PubMed ID: 25803272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
    Wang C; Yang Y; Gao S; Chen J; Yu J; Zhang H; Li M; Zhan X; Li W
    Crit Rev Oncol Hematol; 2018 Feb; 122():123-132. PubMed ID: 29458780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.
    Sallman DA; Tanaka TN; List A; Bejar R
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):613-620. PubMed ID: 29025689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells.
    Wei Y; Chen R; Dimicoli S; Bueso-Ramos C; Neuberg D; Pierce S; Wang H; Yang H; Jia Y; Zheng H; Fang Z; Nguyen M; Ganan-Gomez I; Ebert B; Levine R; Kantarjian H; Garcia-Manero G
    Leukemia; 2013 Nov; 27(11):2177-86. PubMed ID: 23538751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
    Tauro S; Hepburn MD; Bowen DT; Pippard MJ
    Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes.
    Sallman DA; List A
    Blood; 2019 Mar; 133(10):1039-1048. PubMed ID: 30670444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.